c-Met/CD3 Bispecific Antibody(Tongji University)

N/A

Report date: 2026/03/19 17:16:26

Base Information

Drug Namec-Met/CD3 Bispecific Antibody(Tongji University)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-Hepatocyte growth factor receptorAnti-CD3
TargetsHepatocyte growth factor receptorT cell surface glycoprotein CD3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesTongji University
China Registration ClassN/A

Develop Information

Active CompaniesTongji University
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A